Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed or refractory follicular lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study.

导出 LinkOut

翻译打印收藏纠错

作者： Catherine,Diefenbach ^[1] ; Brad S,Kahl ^[2] ; Andrew,McMillan ^[3] ; Javier,Briones ^[4] ; Lalita,Banerjee ^[5] ; Raul,Cordoba ^[6] ; Fiona,Miall ^[7] ; John M,Burke ^[8] ; Jamie,Hirata ^[9] ; Yanwen,Jiang ^[9] ; Joseph N,Paulson ^[9] ; Yi Meng,Chang ^[10] ; Lisa,Musick ^[9] ; Pau,Abrisqueta ^[11]

作者单位： Perlmutter Cancer Center at New York University Langone Health, New York, NY, USA. Electronic address: catherine.diefenbach@nyulangone.org. ^[1] Division of Oncology, Washington University, St Louis, MO, USA. ^[2] Centre for Clinical Haematology, Nottingham University Hospitals NHS Trust, Nottingham, UK. ^[3] Department of Hematology, Hospital Santa Creu i Sant Pau, Barcelona, Spain. ^[4] Oncology Centre, Maidstone and Tunbridge Wells NHS Trust, Maidstone, UK. ^[5] Fundacion Jimenez Diaz University Hospital, Madrid, Spain. ^[6] Department of Haematology, University Hospitals of Leicester NHS Trust, Leicester, UK. ^[7] Rocky Mountain Cancer Centers and US Oncology, Aurora, CO, USA. ^[8] Genentech, South San Francisco, CA, USA. ^[9] F Hoffmann-La Roche, Mississauga, OT, Canada. ^[10] Department of Hematology, Hospital Vall Hebron, Barcelona, Spain. ^[11]

主题词青少年(Adolescent);成年人(Adult);抗体, 单克隆(Antibodies, Monoclonal);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);女(雌)性(Female);人类(Humans);免疫轭合物(Immunoconjugates);淋巴瘤, 滤泡性(Lymphoma, Follicular);男(雄)性(Male);肿瘤复发, 局部(Neoplasm Recurrence, Local);治疗结果(Treatment Outcome)

DOI 10.1016/S2352-3026(21)00311-2

PMID 34826412

发布时间 2022-05-31

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览1

The Lancet. Haematology

2021年8卷12期

e891-e901页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed or refractory follicular lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study.

The Lancet. Haematology

相似文献

The Lancet. Haematology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed or refractory follicular lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study.

The Lancet. Haematology

相似文献

The Lancet. Haematology

相关期刊

检索历史清除